Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Nursing & Healthcare International Journal Research Article 19 min read

Alternative Measures for IBS Management

Mohiuddin AK*
* Corresponding author
ISSN: 2575-9981  10.23880/nhij-16000204  Received: September 25, 2019  Published: October 11, 2019
 — views
 153 references
 1 figure
PDF
Keywords
Irritable Bowel Syndrome Low-FODMAP Cognitive behavioral therapy Complementary and Alternative Medicine Chinese Herbal Medicine Brain–gut axis
Abstract

About 30% to 40% of adults claim to have frequent indigestion, and over 50 million visits are made annually to ambulatory care facilities for symptoms related to the digestive system. Irritable bowel syndrome (IBS) is present in patients with symptoms of chronic abdominal pain and altered bowel habits but no identifiable organic etiology. IBS has a prevalence of 1% to 20% worldwide; although up to 75% affected individuals never seek care. Diagnosing IBS can be challenging due to the nonspecific nature of symptoms, overlapping upper and lower abdominal symptoms, and the frequent presence of somatic and psychological comorbidities. Up to 80% of IBS patients identify food as a possible trigger for their symptoms, so they increasingly ask for dietary and behavioral counseling. Moderate-severe IBS is estimated to account for around 60% of all IBS cases and has been shown to impose a considerable burden on patients. It is estimated that IBS-C accounts for around 30% of IBS cases. The economic burden of IBS in the US is estimated at $28 billion annually; a portion of these costs may be related to unnecessary and high-frequency tests, although few studies have assessed the factors underlying frequent tests and procedures among patients with IBS. 32% of IBS-C patients suffer depression as their condition almost every day in the previous month. Sexual dysfunction is positively associated with perceived GI symptom severity and HRQoL.

Acknowledgement

I’m thankful to Dr. Elshazaly Saeed F.E.H. Elhassan, King Saud University, Saudi Arabia for his precious time to review my literature and for her thoughtful suggestions. I’m also grateful to seminar library of Faculty of Pharmacy, University of Dhaka and BANSDOC Library, Bangladesh for providing me books, journal and newsletters. Conflict of Interest: The author declares that he has no competing interests.

Figure 1: Irritable Bowel Syndrome [1-4].
Click to enlarge
Figure 1: Irritable Bowel Syndrome [1-4].

References

  1. Okawa Y, Fukudo S, Sanada H (2019) Specific foods can reduce symptoms of irritable bowel syndrome and functional constipation: a review. Biopsychosoc Med 13: 10.
  2. Abdul Rani R, Raja Ali RA, Lee YY (2016) Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. Intest Res 14(4): 297-304.
  3. Mohiuddin AK (2019) Alternative Treatments for Minor GI Ailments. INNOVATIONS in pharmacy 10(3).
  4. Patel N, Shackelford KS (2019) Irritable Syndrome Syndrome. In: StatPearls Treasure Island (FL): StatPearls Publishing.
  5. Rahimi R, Abdollahi M (2012) Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol 18(7): 589-600.
  6. Wu JC (2010) Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths? Gastroenterol Hepatol (N Y) 6(11): 705-711.
  7. Adeyemo MA, Chang L (2008) New treatments for irritable bowel syndrome in women. Womens Health (Lond) 4(6): 605-622.
  8. Peyton L, Greene J (2014) Irritable bowel syndrome: current and emerging treatment options. P T 39(8): 567-578.
  9. Anastasi JK, Capili B, Chang M (2013) Managing irritable bowel syndrome. Am J Nurs 113(7): 42-53.
  10. Larussa T, Rossi M, Suraci E, Marasco R, Imeneo M, et al. (2019) Use of Complementary and Alternative Medicine by Patients with Irritable Bowel Syndrome According to the Roma IV Criteria: A Single-Center Italian Survey. Medicina (Kaunas) 55(2): 46.
  11. Nguyen L (2018) Complementary and Alternative Medicine for the Management of Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 14(9): 536- 538.
  12. Shen YH, Nahas R (2009) Complementary and alternative medicine for treatment of irritable bowel syndrome. Can Fam Physician 55(2): 143-148.
  13. Chiarioni G, Pesce M, Fantin A, Sarnelli G (2018) Complementary and alternative treatment in functional dyspepsia. United European Gastroenterol J 6(1): 5-12.
  14. Tabish SA (2008) Complementary and Alternative Healthcare: Is it Evidence-based?. Int J Health Sci (Qassim) 2(1): 5-9.
  15. Callahan LF, Wiley-Exley EK, Mielenz TJ, Brady TJ, Xiao C, et al. (2009) Use of complementary and alternative medicine among patients with arthritis. Prev Chronic Dis 6(2): 44.
  16. Goldenberg JZ, Steel A, Day A, Yap C, Bradley R, et al. (2018) Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics. Integr Med Res 7(3): 279-286.
  17. Lail G, Luck N, Tasneem AA, Rai A, Laeeq SM, et al. (2016) The usage of complementary and alternative medicine in gastrointestinal patients visiting the outpatients' department of a large tertiary care centre-views from Pakistan. Pan Afr Med J 24: 247.
  18. Brien SB, Bishop FL, Riggs K, Stevenson D, Freire V, et al. (2011) Integrated medicine in the management of chronic illness: a qualitative study. Br J Gen Pract 61(583): 89-96.
  19. Grundmann O, Yoon SL (2014) Complementary and alternative medicines in irritable bowel syndrome: an integrative view. World J Gastroenterol 20(2): 346- 362.
  20. Harris LR, Roberts L (2008) Treatments for irritable bowel syndrome: patients' attitudes and acceptability. BMC Complement Altern Med 8: 65.
  21. Hussain Z, Quigley EM (2006) Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 23(4): 465-471.
  22. Lee U, Fox P, Lafarge C, Mitchell K (2019) Factors Associated With Complementary and Alternative Medicine Use in Irritable Bowel Syndrome: A Literature Review. Psychology, Community & Health 2(3): 346-361.
  23. Jadallah KA, Kullab SM, Sanders DS (2014) Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 20(27): 8898-8909.
  24. Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, et al. (2017) New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 23(36): 6593-6627.
  25. Lang L (2008) The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology 135(1): 7.
  26. Sweetser S, Busciglio IA, Camilleri M, Bharucha AE, Szarka LA, et al. (2009) Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol 296(2): 295-301.
  27. Moayyedi P, Mearin F, Azpiroz F, Andresen V, Barbara G, et al. (2017) Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterol J 5(6): 773- 788.
  28. Tameez Ud Din A, Khan AH, Bajwa H, Maqsood MH, Malik MN (2019) Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation. Cureus 11(4): 4382.
  29. Evangelista S (2012) Benefits from Long-Term Treatment in Irritable Bowel Syndrome. Gastroenterol Res Pract 2012: 936960.
  30. Quigley EMM (2017) Prokinetics in the Management of Functional Gastrointestinal Disorders. Curr Gastroenterol Rep 19(10): 53.
  31. Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, et al. (2014) Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol 20(27): 8807-8820.
  32. Tack J, Stanghellini V, Mearin F, Yiannakou Y, Layer P, et al. (2019) Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol 19(1): 69.
  33. Wang XJ, Camilleri M (2019) Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy. World J Gastroenterol 25(10): 1185-1196.
  34. Talley NJ (2003) Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 56(4): 362-369.
  35. Occhipinti K, Smith JW (2012) Irritable bowel syndrome: A review and update. Clin Colon Rectal Surg 25(1): 46-52.
  36. Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, et al. (2015) Optimal management of constipation associated with irritable bowel syndrome. Ther Clin Risk Manag 11: 691-703.
  37. Annaházi A, Róka R, Rosztóczy A, Wittmann T (2014) Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol 20(20): 6031-6043.
  38. Reina J, Smith JW (2005) Medical treatment of irritable bowel syndrome. Clin Colon Rectal Surg 18(2): 102-108.
  39. Hammerle CW, Surawicz CM (2008) Updates on treatment of irritable bowel syndrome. World J Gastroenterol 14(17): 2639-2649.
  40. Basnayake C (2018) Treatment of irritable bowel syndrome. Aust Prescr 41(5): 145-149.
  41. US FDA Admin Web. Zelnorm (tegaserod maleate) Information.
  42. Key Point. Tegaserod withdrawn from U.S. market. APhA Drug Info Online Web April 1, 2007.
  43. WHO Web. Alosetron - withdrawn: severe adverse reactions.
  44. Charatan F (2002) FDA advisory panels recommend Lotronex be put back on market. BMJ 324(7345): 1053.
  45. Moynihan R (2002) Alosetron: a case study in regulatory capture, or a victory for patients' rights?. BMJ 325(7364): 592-595.
  46. Lucak SL (2010) Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol 3(3): 165-172.
  47. Lacy BE, Nicandro JP, Chuang E, Earnest DL (2018) Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. Therap Adv Gastroenterol 11: 1756284818771674.
  48. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: irritable bowel syndrome-clinical evaluation of drugs for treatment.
  49. Hawrelak JA, Myers SP (2010) Effects of two natural medicine formulations onirritable bowel syndrome symptoms: a pilot study. J Altern Complement Med 16(10): 1065-1071.
  50. Bahrami HR, Hamedi S, Salari R, Noras M (2016) Herbal Medicines for the Management of Irritable Bowel Syndrome: A Systematic Review. Electron Physician 8(8): 2719-2725.
  51. National Collaborating Centre for Nursing and Supportive Care (UK) (2008) Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care. London: Royal College of Nursing (UK), (NICE Clinical Guidelines, No. 61.) Diet and lifestyle.
  52. Alammar N, Wang L, Saberi B, Nanavati J, Holtmann G, et al. (2019) The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med 19(1): 21.
  53. Khanna R, MacDonald JK, Levesque BG (2014) Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 48(6): 505-512.
  54. Cash BD, Epstein MS, Shah SM (2016) A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci 61(2): 560-571.
  55. Grigoleit HG, Grigoleit P (2005) Peppermint oil in irritable bowel syndrome. Phytomedicine 12(8): 601- 606.
  56. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, et al. (2010) The effect of enteric-coated, delayed- release peppermint oil on irritable bowel syndrome. Dig Dis Sci 55(5): 1385-1390.
  57. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L (2007) Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 39(6): 530-536.
  58. Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR (2014) Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol 20(27): 8796-8806.
  59. Chumpitazi BP, Kearns GL, Shulman RJ (2018) Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. Aliment Pharmacol Ther 47(6): 738-752.
  60. Fifi AC, Axelrod CH, Chakraborty P, Saps M (2018) Herbs and Spices in the Treatment of Functional Gastrointestinal Disorders: A Review of Clinical Trials. Nutrients 10(11) pii: E1715.
  61. Gundermann KJ, Vinson B, Hänicke S (2004) Functional dyspepsia in children - A retrospective study of a phytopharmaceutical. Päd 10: 1-6.
  62. Malfertheiner P (2017) STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders. Dig Dis Suppl 1: 25-29.
  63. Ottillinger B, Storr M, Malfertheiner P, Allescher HD (2013) STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 163(3-4): 65-72.
  64. Lapina TL, Trukhmanov AS (2017) Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice. Dig Dis Suppl 1: 30-35.
  65. Allescher HD, Abdel Aziz H (2017) Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target. Dig Dis Suppl 1: 18-24.
  66. Raedsch R, Vinson B, Ottillinger B, Holtmann G (2018) Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast®. Wien Med Wochenschr 168(3-4): 89-98.
  67. Mearin F, Malfertheiner P (2018) Functional Gastrointestinal Disorders: Complex Treatments for Complex Pathophysiological Mechanisms. Dig Dis 35(1): 1-4.
  68. Abdel Aziz H, Kelber O, Lorkowski G, Storr M (2017) Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast. Planta Med 83(14-15): 1130-1140.
  69. Ochoa Cortes F, Liñán Rico A, Jacobson KA, Christofi FL (2017) Potential for developing purinergic drugs for gastrointestinal diseases. Inflamm Bowel Dis 20(7): 1259-1287.
  70. Madisch A, Vinson BR, Abdel-Aziz H, Kelber O, Nieber K, et al. (2017) Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders. Wien Med Wochenschr 167(7-8): 160-168.
  71. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, et al. (2018) A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS). J Clin Med 7(10) E298.
  72. Bundy R, Walker AF, Middleton RW, Booth J (2004) Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 10(6): 1015- 1018.
  73. Dulbecco P, Savarino V (2013) Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol 19(48): 9256-9709.
  74. Kandola A (2018) Turmeric for IBS: Does it work?
  75. Micucci M, Aldini R, Cevenini M, Colliva C, Spinozzi S, et al. (2013) Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse. PLoS One 8(11): e80925.
  76. Khan I, Samson SE, Grover AK (2017) Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. Med Princ Pract 26(3): 201-217.
  77. Di Ciaula A, Portincasa P, Maes N, Albert A (2018) Efficacy of bio-optimized extracts of turmeric and essential fennel oil on the quality of life in patients with irritable bowel syndrome. Ann Gastroenterol 31(6): 685-691.
  78. Portincasa P, Bonfrate L, de Bari O, Lembo A, Ballou S (2017) Irritable bowel syndrome and diet. Gastroenterol Rep (Oxf) 5(1): 11-19.
  79. Portincasa P, Bonfrate L, Scribano ML, Kohn A, Caporaso N, et al. (2016) Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome. J Gastrointestin Liver Dis 25(2): 151-157.
  80. Lakhan SE, Ford CT, Tepper D (2015) Zingiberaceae extracts for pain: a systematic review and meta- analysis. Nutr J 14: 50.
  81. Russo EB (2008) Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 4(1): 245- 259.
  82. Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M, et al. (2012) Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil 24(4): 358-e169.
  83. Klooker TK, Leliefeld KE, Van Den Wijngaard RM, Boeckxstaens GE (20110 The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol Motil 23(1): 30-55.
  84. Bokic T, Storr M, Schicho R (2015) Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. Pharmacology 96(1-2): 76- 85.
  85. Fraguas Sánchez AI, Torres Suárez AI (2018) Medical Use of Cannabinoids. Drugs 78(16): 1665-1703.
  86. Halawi H, Camilleri M (2017) Pharmacogenetics and the treatment of functional gastrointestinal disorders. Pharmacogenomics 18(11): 1085-1094.
  87. Davis K, Philpott S, Kumar D, Mendall M (2006) Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int J Clin Pract 60(9): 1080-1086.
  88. Hutchings HA, Wareham K, Baxter JN, Atherton P, Kingham JG, et al. (2011) A Randomised, Cross-Over, Placebo-Controlled Study of Aloe vera in Patients with Irritable Bowel Syndrome: Effects on Patient Quality of Life. ISRN Gastroenterol 2011: 206103.
  89. Størsrud S, Pontén I, Simrén M (2015) A Pilot Study of the Effect of Aloe barbadensis Mill. Extract (AVH200®) in Patients with Irritable Bowel Syndrome: a Randomized, Double-Blind, Placebo- Controlled Study. J Gastrointestin Liver Dis 24(3): 275-280.
  90. Hong SW, Chun J, Park S, Lee HJ, Im JP, et al. (2018) Aloe vera is Effective and Safe in Short-term Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. J Neurogastroenterol Motil 24(4): 528-535.
  91. Khedmat H, Karbasi A, Amini M, Aghaei A, Taheri S (2013) Aloe vera in treatment of refractory irritable bowel syndrome: Trial on Iranian patients. J Res Med Sci 18(8): 732.
  92. Kandola A (2018) Is Aloe vera juice good for IBS?
  93. Foster M, Hunter D, Samman S (2011) Evaluation of the Nutritional and Metabolic Effects of Aloe vera. In: Benzie IFF, et al. (Eds), Herbal Medicine: Biomolecular and Clinical Aspects. 2nd(edn), Boca Raton (FL), (Chapter 3), CRC Press/Taylor & Francis.
  94. Lacy BE, Weiser K, De Lee R (2009) The treatment of irritable bowel syndrome. Therap Adv Gastroenterol 2(4): 221-238.
  95. Guo X, Mei N (2016) Aloe vera: A review of toxicity and adverse clinical effects. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 34(2): 77-96.
  96. Boudreau MD, Mellick PW, Olson GR, Felton RP, Thorn BT, et al. (2013) Clear evidence of carcinogenic activity by a whole-leaf extract of Aloe barbadensis miller (aloe vera) in F344/N rats. Toxicol Sci 131(1): 26-39.
  97. Boudreau MD, Beland FA, Nichols JA, Pogribna M (2013) Toxicology and carcinogenesis studies of a nondecolorized [corrected] whole leaf extract of Aloe barbadensis Miller (Aloe vera) in F344/N rats and B6C3F1 mice (drinking water study). Natl Toxicol Program Tech Rep Ser (577): 1-266.
  98. Boudreau MD, Olson GR, Tryndyak VP, Bryant MS, Felton RP, et al. (2017) From the Cover: Aloin, a Component of the Aloe Vera Plant Leaf, Induces Pathological Changes and Modulates the Composition of Microbiota in the Large Intestines of F344/N Male Rats. Toxicol Sci 158(2): 302-318.
  99. Yang HN, Kim DJ, Kim YM, Kim BH, Sohn KM, et al. (2010) Aloe-induced toxic hepatitis. J Korean Med Sci 25(3): 492-495.
  100. Bottenberg MM, Wall GC, Harvey RL, Habib S (2007) Oral aloe vera-induced hepatitis. Ann Pharmacother 41(10): 1740-1743.
  101. Lee J, Lee MS, Nam KW (2014) Acute toxic hepatitis caused by an aloe vera preparation in a young patient: a case report with a literature review. Korean J Gastroenterol 64(1): 54-58.
  102. Curciarello J, De Ortúzar S, Borzi S, Bosia D (2008) Severe acute hepatitis associated with intake of Aloe vera tea. Gastroenterol Hepatol 31(7): 436-48.
  103. Frenzel C, Teschke R (2016) Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation. Int J Mol Sci 17(5).
  104. Saka W, Akhigbe R, Popoola O, Oyekunle O (2012) Changes in Serum Electrolytes, Urea, and Creatinine in Aloe Vera-treated Rats. J Young Pharm 4(2): 78-81.
  105. van Tilburg MA, Palsson OS, Ringel Y, Whitehead WE (2014) Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. Complement Ther Med 22(1): 17-20.
  106. Yuki M, Komazawa Y, Kobayashi Y, Kusunoki M, Takahashi Y, et al. (2015) Effects of Daikenchuto on Abdominal Bloating Accompanied by Chronic Constipation: A Prospective, Single-Center Randomized Open Trial. Curr Ther Res Clin Exp 77: 58-62.
  107. Hu ML, Rayner CK, Wu KL, Chuah SK, Tai WC, et al. (2011) Effect of ginger on gastric motility and symptoms of functional dyspepsia. World J Gastroenterol 17(1): 105-110.
  108. Nikkhah Bodagh M, Maleki I, Hekmatdoost A (2018) Ginger in gastrointestinal disorders: A systematic review of clinical trials. Food Sci Nutr 7(1): 96-108.
  109. Kazemian A, Toghiani A, Shafiei K, Afshar H, Rafiei R, et al. (2017) Evaluating the efficacy of mixture of Boswellia carterii, Zingiber officinale, and Achillea millefolium on severity of symptoms, anxiety, and depression in irritable bowel syndrome patients. J Res Med Sci 22: 120.
  110. Sahib AS (2013) Treatment of irritable bowel syndrome using a selected herbal combination of Iraqi folk medicines. J Ethnopharmacol 148(3): 1008- 1012.
  111. Lichtenstein GR (2018) Brain-Gut Therapies and Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 14(7): 399.
  112. Lin SC, Cheifetz AS (2018) The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 14(7): 415-425.
  113. Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, et al. (2019) Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol 2(1): 6-29.
  114. Yan J, Miao ZW, Lu J, Ge F, Yu LH, et al. (2019) Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2019: 7680963.
  115. Wu IXY, Wong CHL, Ho RST, Cheung WKW, Ford AC, et al. (2019) Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. Therap Adv Gastroenterol 12: 1756284818820438.
  116. Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, et al. (2012) Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev (5): CD005111.
  117. Chao GQ, Zhang S (2014) Effectiveness of acupuncture to treat irritable bowel syndrome: a meta-analysis. World J Gastroenterol 20(7): 1871- 1877.
  118. Li CY, Li SC (2015) Treatment of irritable bowel syndrome in China: a review. World J Gastroenterol 21(8): 2315-2322.
  119. Ma XP, Hong J, An CP, Zhang D, Huang Y, et al. (2014) Acupuncture-moxibustion in treating irritable bowel syndrome: how does it work? World J Gastroenterol 20(20): 6044-6054.
  120. Anastasi JK, Capili B (2012) The Treatment of Constipation-Predominant Irritable Bowel Syndrome with Acupuncture and Moxibustion: A Case Report. J Chin Med 99: 68-71.
  121. Anastasi JK, Capili B, Chang M (2017) Development of Acupuncture and Moxibustion Protocol in a Clinical Trial for Irritable Bowel Syndrome. J Acupunct Meridian Stud 10(1): 62-66.
  122. Lin X, Liu X, Xu J, Cheng KK, Cao J, et al. (2019) Metabolomics analysis of herb-partitioned moxibustion treatment on rats with diarrhea- predominant irritable bowel syndrome. Chin Med 14: 18.
  123. Park JW, Lee BH, Lee H (2013) Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. BMC Complement Altern Med. 13: 247.
  124. Manheimer E, Wieland LS, Cheng K, Li SM, Shen X, (2012) Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 107(6): 835-847.
  125. Forbes A, Jackson S, Walter C, Quraishi S, Jacyna M, et al. (2005) Acupuncture for irritable bowel syndrome: a blinded placebo-controlled trial. World J Gastroenterol 11(26): 4040-4044.
  126. Teschke R, Wolff A, Frenzel C, Eickhoff A, Schulze J (2015) Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders. World J Gastroenterol 21(15): 4466-4490.
  127. Riehl ME (2018) The Emerging Role of Brain-Gut Therapies for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 14(7): 436-438.
  128. Kinsinger SW (2017) Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights. Psychol Res Behav Manag 10: 231-237.
  129. Flik CE, Laan W, Zuithoff NPA, van Rood YR, Smout AJPM, et al. (2019) Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol 4(1): 20-31.
  130. Hasan SS, Pearson JS, Morris J, Whorwell PJ (2019) Skype Hypnotherapy for Irritable Bowel Syndrome: Effectiveness and Comparison with Face-to-Face Treatment. Int J Clin Exp Hypn 67(1): 69-80.
  131. Vasant DH, Whorwell PJ (2019) Gut-focused hypnotherapy for Functional Gastrointestinal Disorders: Evidence-base, practical aspects, and the Manchester Protocol. Neurogastroenterol Motil 31(8): 1-12.
  132. Lee HH, Choi YY, Choi MG (2014) The Efficacy of Hypnotherapy in the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. J Neurogastroenterol Motil 20(2): 152-162.
  133. Peter J, Fournier C, Keip B, Rittershaus N, Stephanou- Rieser N, et al. (2018) Intestinal Microbiome in Irritable Bowel Syndrome before and after Gut- Directed Hypnotherapy. Int J Mol Sci 19(11).
  134. Kawanishi H, Sekiguchi A, Funaba M, Fujii Y, Yoshiuchi K, et al. (2019) Cognitive behavioral therapy with interoceptive exposure and complementary video materials for irritable bowel syndrome (IBS): protocol for a multicenter randomized controlled trial in Japan. Biopsychosoc Med 13: 14.
  135. Lackner JM, Jaccard J, Keefer L, Brenner DM, Firth RS, et al. (2018) Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome. Gastroenterology 155(1): 47-57.
  136. Lackner JM, Jaccard J, Radziwon CD, Firth RS, Gudleski GD, et al. (2019) Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up. Am J Gastroenterol 114(2): 330-338.
  137. Everitt HA, Landau S, O'Reilly G, Sibelli A, Hughes S, et al. (2019) Assessing telephone-delivered cognitive- behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut 68(9): 1613-1623.
  138. Radu M, Moldovan R, Pintea S, Băban A, Dumitrascu D (2018) Predictors of outcome in cognitive and behavioural interventions for irritable bowel syndrome. A meta-analysis. J Gastrointestin Liver Dis 27(3): 257-263.
  139. Zhou C, Zhao E, Li Y, Jia Y, Li F (2019) Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials. Neurogastroenterol Motil 31(2): e13461.
  140. Evans S, Seidman LC, Lung K, Sternlieb B, Zeltzer LK (2018) Yoga for Teens With Irritable Bowel Syndrome: Results From a Mixed-Methods Pilot Study. Holist Nurs Pract 32(5): 253-260.
  141. Evans S, Lung KC, Seidman LC, Sternlieb B, Zeltzer LK, et al. (2014) Iyengar yoga for adolescents and young adults with irritable bowel syndrome. J Pediatr Gastroenterol Nutr 59(2): 244-253.
  142. Patel N, Lacy B (2016) Does Yoga Help Patients With Irritable Bowel Syndrome? Clinical Gastroenterology and Hepatology 14: 1732-1734.
  143. Cramer H, Lauche R, Dobos G (2014) Characteristics of randomized controlled trials of yoga: a bibliometric analysis. BMC Complement Altern Med 14: 328.
  144. Schumann D, Langhorst J, Dobos G, Cramer H (2018) Randomised clinical trial: yoga vs a low-FODMAP diet in patients with irritable bowel syndrome. Aliment Pharmacol Ther 47(2): 203-211.
  145. Reddel S, Putignani L, Del Chierico F (2019) The Impact of Low-FODMAPs, Gluten-Free, and Ketogenic Diets on Gut Microbiota Modulation in Pathological Conditions. Nutrients 11(2).
  146. Staudacher HM, Ralph FSE, Irving PM, Whelan K, Lomer MCE (2019) Nutrient Intake, Diet Quality, and Diet Diversity in Irritable Bowel Syndrome and the Impact of the Low FODMAP Diet. J Acad Nutr Diet pii: S2212-2672(18)31829-X.
  147. Kortlever TL, Ten Bokkel Huinink S, Offereins M, Hebblethwaite C, O'Brien L, et al. (2019) Low- FODMAP Diet Is Associated With Improved Quality of Life in IBS Patients-A Prospective Observational Study. Nutr Clin Pract 34(4): 623-630.
  148. Eswaran S, Dolan RD, Ball SC, Jackson K, Chey W (2019) The Impact of a 4-Week Low-FODMAP and mNICE Diet on Nutrient Intake in a Sample of US Adults with Irritable Bowel Syndrome with Diarrhea. J Acad Nutr Diet pii: S2212-2672(18)31544-2.
  149. Mari A, Hosadurg D, Martin L, Zarate-Lopez N, Passananti V, Emmanuel A (2019) Adherence with a low-FODMAP diet in irritable bowel syndrome: are eating disorders the missing link? Eur J Gastroenterol Hepatol 31(2): 178-182.
  150. Mitchell H, Porter J, Gibson PR, Barrett J, Garg M (2019) Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome-directions for future research. Aliment Pharmacol Ther 49(2): 124-139.
  151. Ooi SL, Correa D, Pak SC (2019) Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome - What is the current evidence? Complement Ther Med 43: 73-80.
  152. Jankovich E, Watkins S (2017) The Low FODMAP Diet Reduced Symptoms in a Patient With Endometriosis and IBS. South African Journal of Clinical Nutrition 30(4): 32-36.
  153. El-Salhy M, Ystad SO, Mazzawi T, Gundersen D (2017) Dietary fiber in irritable bowel syndrome (Review). Int J Mol Med 40(3): 607-613.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{mohiuddin2019,
  title   = {Alternative Measures for IBS Management},
  author  = {Mohiuddin AK},
  journal = {Nursing & Healthcare International Journal},
  year    = {2019},
  volume  = {3},
  number  = {5},
  doi     = {10.23880/nhij-16000204}
}
Mohiuddin AK (2019). Alternative Measures for IBS Management. Nursing & Healthcare International Journal, 3(5). https://doi.org/10.23880/nhij-16000204
TY  - JOUR
TI  - Alternative Measures for IBS Management
AU  - Mohiuddin AK
JO  - Nursing & Healthcare International Journal
PY  - 2019
VL  - 3
IS  - 5
DO  - 10.23880/nhij-16000204
ER  -